UBS Group’s Impax Laboratories, Inc. IPXL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q2 | – | Sell |
-105,315
| Closed | -$2.05M | – | 8570 |
|
|
2018
Q1 | $2.05M | Sell |
105,315
-3,444
| -3% | -$67.6K | ﹤0.01% | 3118 |
|
|
2017
Q4 | $1.81M | Buy |
108,759
+29,497
| +37% | +$541K | ﹤0.01% | 3272 |
|
|
2017
Q3 | $1.61M | Buy |
79,262
+38,411
| +94% | +$734K | ﹤0.01% | 3312 |
|
|
2017
Q2 | $658K | Buy |
40,851
+10,210
| +33% | +$151K | ﹤0.01% | 3925 |
|
|
2017
Q1 | $387K | Sell |
30,641
-14,726
| -32% | -$178K | ﹤0.01% | 4226 |
|
|
2016
Q4 | $601K | Sell |
45,367
-32,937
| -42% | -$563K | ﹤0.01% | 3970 |
|
|
2016
Q3 | $1.86M | Buy |
78,304
+42,850
| +121% | +$1.15M | ﹤0.01% | 2911 |
|
|
2016
Q2 | $1.02M | Sell |
35,454
-2,973
| -8% | -$96.9K | ﹤0.01% | 3360 |
|
|
2016
Q1 | $1.23M | Buy |
38,427
+742
| +2% | +$26.1K | ﹤0.01% | 3088 |
|
|
2015
Q4 | $1.61M | Buy |
37,685
+30,209
| +404% | +$1.21M | ﹤0.01% | 3011 |
|
|
2015
Q3 | $263K | Sell |
7,476
-20,514
| -73% | -$924K | ﹤0.01% | 4423 |
|
|
2015
Q2 | $1.29M | Buy |
27,990
+11,151
| +66% | +$529K | ﹤0.01% | 3368 |
|
|
2015
Q1 | $789K | Sell |
16,839
-113,142
| -87% | -$4.5M | ﹤0.01% | 3777 |
|
|
2014
Q4 | $4.12M | Buy |
+129,981
| New | +$3.8M | ﹤0.01% | 2263 |
|
UBS Group's IPXL Position: Q2 2018 in Review
UBS Group sold out of Impax Laboratories, Inc. (IPXL) in Q2 2018, closing a stake of 105,315 shares — an estimated $2.05M sold.
UBS Group first reported a position in IPXL in Q4 2014 and held it in 14 quarters. The position peaked at $4.12M in Q4 2014. 1 fund tracked by Wall St. Rank holds IPXL as of Q2 2018.
- UBS Group reported no remaining Impax Laboratories, Inc. position as of Q2 2018 after selling out during the quarter.
- UBS Group sold 105,315 Impax Laboratories, Inc. shares in Q2 2018, an estimated $2.05M.
- UBS Group first reported a position in Impax Laboratories, Inc. in Q4 2014 and held it in 14 quarters.
- UBS Group's Impax Laboratories, Inc. position peaked at $4.12M in Q4 2014.
- 1 fund tracked by Wall St. Rank held Impax Laboratories, Inc. as of Q2 2018.
Based on UBS Group's 13F filing for Q2 2018, filed 14 Aug 2018.